EGFR and neoplasm: PFS was improved with EGFR-TKIs in combination with bevacizumab compared to EGFR-TKIs monotherapy, particularly in the NEJ026 trial and several others [20,22,29,34], suggesting improved PFS with bevacizumab is potentially due to increasing drug distribution and tumor-suppressive effects.